97 completed, 49 unknown, 30 recruiting, 30 terminated. 95 Phase 2, 71 Phase 3, 30 Not applicable, 29 Phase 1, 16 Phase 4.
Follow Mitomycin: new trials by email Literature Review of Mitomycin trials Research Report on Mitomycin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study Toripalimab, Gemcitabine (GEM), Mitomycin C (MMC) - Urinary Bladder Neoplasms, Carcinoma, Transitional Cell | Phase 2 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 106 | 2026-12-01 | 2026-09-08 |
| Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived Organoids Epirubicin, Mitomycin, Gemcitabine - Bladder Cancer, Non-muscle Invasive Bladder Cancer | Phase 2 | Not yet recruiting | Hospital Centre Biel/Bienne | 28 | 2026-12-01 | 2026-09-18 |
| Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma | Phase 3 | Recruiting | City of Hope Medical Center | 129 | 2026-10-01 | 2026-09-25 |
| Combined Systemic and Intraperitoneal Chemotherapy for Synchronous Gastric and/or Gastroesophageal Peritoneal Carcinomatosis Cisplatin, Mitomycin C - Synchronous Gastric Peritoneal Carcinomatosis, Gastroesophageal Peritoneal Carcinomatosis | Phase 2 | Recruiting | Mohammad Haroon Asif Choudry | 22 | 2026-09-29 | 2026-10-22 |
| Bladder Preservation or Cystectomy for MIBC Gemzar, Cisplatin, Adrucil - Muscle-Invasive Bladder Carcinoma, Bladder Cancer | Early Phase 1 | Active not recruiting | Dana-Farber Cancer Institute | 20 | 2026-09-02 | 2026-09-15 |
| Active Surveillance Versus Adjuvant Intravesical Chemotherapy in Liquid Biopsy-Defined Low-Shedding Intermediate-Risk NMIBC Active Surveillance, Adjuvant Intravesical Chemotherapy - Bladder Cancer, Non-Muscle-Invasive Bladder Cancer (NMIBC) | Not applicable | Recruiting | Tianjin Medical University Second Hospital | 670 | 2026-08-10 | 2026-10-09 |
| Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors Mitomycin C (MMC), Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) - Peritoneal Carcinomatosis | Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 24 | 2026-08-05 | 2026-09-16 |
| A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC SHR-1501 for Injection, BCG for Injection, Epirubicin Hydrochloride for Injection - NMIBC | Phase 3 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 236 | 2026-07-13 | 2026-07-20 |
| Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors Gemcitabine, Mitomycin C, Thalidomide - Solid Tumor Cancer | Phase 2 | Recruiting | Sarcoma Oncology Research Center, LLC | 60 | 2026-06-01 | 2026-06-26 |
| Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer Mitomycin (MM), FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin), Cytoreductive surgery - Locally Advanced Colorectal Cancer | Phase 3 | Recruiting | Maimónides Biomedical Research Institute of Córdoba | 1083 | 2026-05-26 | 2026-06-08 |
| Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309) Enfortumab vedotin, Conventional Radiotherapy, Hypofractionated Radiotherapy - Urothelial Cancer, Urinary Bladder Neoplasms | Phase 3 | Recruiting | Astellas Pharma Global Development, Inc. | 390 | 2026-05-11 | 2026-10-28 |
| Hyaluronic Acid vs Mitomycin-C in External Dacryocystorhinostomy Hyaluronic Acid (HA), Mitomycin -C - Dacryocystitis | Phase 4 | Not yet recruiting | All India Institute of Medical Sciences, Bhubaneswar | 36 | 2026-04-01 | 2026-03-31 |
| Sintilimab Versus Mitomycin in Combination With Capecitabine and IMRT for Limited-stage Anal Squamous Cell Carcinoma Intensity-Modulated Radiotherapy (IMRT), Capecitabine, Sintilimab - Anal Squamous Cell Carcinoma, Limited-stage | Phase 3 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 350 | 2026-03-17 | 2026-07-09 |
| Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study Biospecimen Collection, Cisplatin, Computed Tomography - Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 486 | 2025-10-07 | 2026-10-23 |
| A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer TAR-210, Mitomycin C, Gemcitabine - Non-Muscle Invasive Bladder Neoplasms | Phase 3 | Recruiting | Janssen Research & Development, LLC | 220 | 2025-09-10 | 2026-09-28 |
| Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer Cisplatin, Mitomycin - Gastric Cancer, Peritoneal Carcinomatosis | Phase 2 | Recruiting | University of Chicago | 21 | 2025-09-09 | 2026-09-08 |
| A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer UGN-104 - Upper Urinary Tract Urothelial Carcinoma, Urothelial Carcinoma | Phase 3 | Recruiting | UroGen Pharma Ltd. | 70 | 2025-08-06 | 2026-09-03 |
| Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial Biospecimen Collection, Cisplatin, Computed Tomography - Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 160 | 2025-06-03 | 2026-10-19 |
| Chemoablation Or Bladder Resection With Adjuvant Chemotherapy in Recurrent Non-Muscle Invasive Bladder Cancer Mitomycin c - Non-Muscle Invasive Bladder Cancer | Phase 4 | Recruiting | Jakob Kristian Jakobsen | 272 | 2025-06-01 | 2025-10-03 |
| In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial BCG Solution, Cystoscopy, Docetaxel - Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 40 | 2025-04-21 | 2026-10-08 |
Showing 20 of 233. Sign in to see all of them.
Urinary Bladder Neoplasms (42) · Non-Muscle Invasive Bladder Neoplasms (27) · Glaucoma (24) · Colorectal Neoplasms (21) · Anus Neoplasms (18) · Carcinoma, Transitional Cell (18) · Neoplasm Metastasis (12) · Appendiceal Neoplasms (11) · Carcinoma, Hepatocellular (11) · Stomach Neoplasms (10) · Glaucoma, Open-Angle (9) · Peritoneal Neoplasms (9) · Carcinoma, Non-Small-Cell Lung (8) · Pancreatic Neoplasms (8) · Neoplasms (7)
UroGen Pharma Ltd. (11) · National Cancer Institute (NCI) (10) · European Organisation for Research and Treatment of Cancer - EORTC (4) · Federal University of São Paulo (4) · Shahid Beheshti University of Medical Sciences (4) · Assiut University (3) · City of Hope Medical Center (3) · Janssen Research & Development, LLC (3) · M.D. Anderson Cancer Center (3) · Mayo Clinic (3) · Medical Research Council (3) · Memorial Sloan Kettering Cancer Center (3) · Radiation Therapy Oncology Group (3) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · University of California, San Francisco (3)
United States (108) · United Kingdom (27) · China (19) · Italy (13) · South Korea (11) · France (10) · Germany (10) · Israel (10) · Spain (10) · Egypt (8) · Poland (8) · Belgium (7) · Netherlands (7) · Brazil (6) · Canada (6)
Savino M Di Stasi, MD, PhD (3) · Brian D. Badgwell, MD (2) · Dominique Elias, MD (2) · Ian E. Smith, MD (2) · Jung-Hwan Yoon, M.D., Ph.D. (2) · Louis B Cantor, MD (2) · Martin F. Muers, MD (2) · Parminder Singh (2) · Sandip Prasad, MD (2) · Yoon-Koo Kang, M.D.,Ph.D. (2) · Abdullah Demirtas, MD (1) · Adam Feldman, MD (1) · Adriaan D. Bins, MD PhD (1) · Adrian Hodson (1)
PMID 34125951, PMID 36912740, PMID 41074972, PMID 10937547, PMID 12051882, PMID 16051328, PMID 16157935, PMID 16389183, PMID 16877071, PMID 17122118, PMID 17470859, PMID 17544497, PMID 18430910, PMID 18486741, PMID 19139424, PMID 19171491, PMID 19643599, PMID 19674729, PMID 20354452, PMID 20564111, PMID 20570237, PMID 21109229, PMID 21135251, PMID 21156335, PMID 21831711, PMID 22244522, PMID 22245458, PMID 22287157, PMID 22512481, PMID 22831982, PMID 23150707, PMID 23510863, PMID 24362862, PMID 24490762, PMID 24531027, PMID 25019269, PMID 25680955, PMID 25954110, PMID 26597443, PMID 27519353, PMID 27633880, PMID 28454122, PMID 28643069, PMID 29189540, PMID 29439668, PMID 29477688, PMID 30247524, PMID 30274699, PMID 30390114, PMID 31128146
2023 (4), 2019 (3), P30CA033572 (3), U10CA180820 (3), U10CA021115 (2), U10CA180868 (2), 2014 (1), 2017 (1), 2025 (1), N01CM00070 (1), N01CM62207 (1), P30CA006973 (1), P30CA015083 (1), P30CA016058 (1), P30CA016086 (1)